These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol.
    Author: Välimäki M, Maass L, Harno K, Nikkilä EA.
    Journal: Eur J Clin Pharmacol; 1986; 30(1):17-20. PubMed ID: 3709628.
    Abstract:
    Serum lipoprotein lipid and apoprotein concentrations were determined in 21 hypertensive men during administration of two beta-blockers, penbutolol or atenolol, for 6 months preceded by a 4 week placebo period. Post-heparin plasma lipoprotein lipase and hepatic lipase activities were also measured. There was a trend to an increase of triglyceride and VLDL triglyceride concentrations during penbutolol administration, but the changes were not significant. Penbutolol also increased the total cholesterol by 11% at 3 months (mainly due to increase of VLDL cholesterol), but this effect diminished at 6 months. Atenolol did not cause any significant change in the total cholesterol but increased HDL cholesterol by 7% at 1 month, the change being due to rise of the HDL3. The HDL3 accounted also for a significant decrease of HDL cholesterol seen in the men receiving penbutolol at 6 months. HDL2 cholesterol as well as the LDL/HDL2 cholesterol ratio remained unchanged in both groups. Neither drug consistently influenced the postheparin plasma lipase activities or the serum apoprotein A or B concentrations. In contrast to an earlier study the results suggest that the clinically most important HDL subfraction, the HDL2, remains unaffected during treatment with beta-blockers.
    [Abstract] [Full Text] [Related] [New Search]